

**CLAIMS**

1. A polypeptide specifically inhibiting Akt activity, which consists of an amino acid sequence indicated in SEQ ID NO: 1, 3, 5, 7 or 9 of the sequence listing.
2. A polypeptide consisting of an amino acid sequence wherein one or several amino acids are deleted, substituted or added in the amino acid sequence indicated in SEQ ID NO: 1, 3, 5, 7 or 9 of the sequence listing, and specifically inhibiting Akt activity.
3. A gene DNA encoding a following protein (a) or (b):
  - (a) a polypeptide consisting of an amino acid sequence indicated in SEQ ID NO: 1, 3, 5, 7 or 9;
  - (b) A polypeptide consisting of an amino acid sequence wherein one or several amino acids are deleted, substituted or added in the amino acid sequence indicated in SEQ ID NO: 1, 3, 5, 7 or 9, and specifically inhibiting Akt activity.
4. A DNA consisting of a base sequence indicated in SEQ ID NO: 2, 4, 6, 8, or 10; or part or whole of these sequences, and encoding a polypeptide that specifically inhibits Akt activity.
5. A DNA hybridizing with the DNA according to claim 4 under stringent conditions, and encoding a polypeptide that specifically inhibits Akt activity.
6. A recombinant expression vector, which is constructed by integrating a DNA encoding the polypeptide that specifically

inhibits Akt activity according to any one of claims 3-5 into a gene expression vector.

7. A method for producing a polypeptide that specifically inhibits Akt activity wherein the recombinant expression vector according to claim 6 is introduced into a host cell and expressed.

8. An antibody which is induced by using a polypeptide indicated in SEQ ID NO: 1, 3, 5, 7 or 9 of the sequence listing and specifically binds to the polypeptide.

9. The antibody according to claim 8 wherein the antibody is a monoclonal antibody.

10. The antibody according to claim 8 wherein the antibody is a polyclonal antibody.

11. A specific inhibitor of Akt activity, wherein the polypeptide according to claim 1 or 2 is an active ingredient.

12. The specific inhibitor of Akt activity according to claim 11, wherein the polypeptid is a sequence of an amino acid residue10-24 of an amino acid sequence for human TCL1 protein.

13. The specific inhibitor of Akt activity according to claim 11, wherein the polypeptid is a sequence of an amino acid residue8-22 of an amino acid sequence for human TCL1B protein.

14. The specific inhibitor of Akt activity according to claim

11, wherein the polypeptid is a sequence of an amino acid residue5-19 of an amino acid sequence for human MTP1 protein.

15. The specific inhibitor of Akt activity according to claim 11, wherein the polypeptid is a sequence of an amino acid residue9-24 of an amino acid sequence for mouse TCL1 protein.

16. The specific inhibitor of Akt activity according to claim 11, wherein the polypeptid is a sequence of an amino acid residue9-24 of an amino acid sequence for rat MTP1 protein.

17. The specific inhibitor of Akt activity according to any one of claims 11-16, wherein specific inhibition of Akt activity is the inhibition of binding of phsphoinositide to Akt.

18. An antitumor agent wherein the polypeptide according to claim 1 or 2 is an active ingredient.

19. The antitumor agent according to claim 18, wherein the antitumor agent is an agent for prevention or treatment of malignancy.

20. The antitumor agent according to claim 19, wherein treatment of malignancy is prevention or treatment of breast cancer, lung cancer, leukemia or lymphoid tumor.

21. A method for specifically inhibiting Akt activity by introducing a DNA encoding the polypeptide that specifically inhibits Akt activity according to any one of claims 3-5 into living cells to express the polypeptide.